Sollus Therapeutics, Inc.
Publicly observedChapel Hill, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Chapel Hill | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Sollus Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | L6W7MCAYEBE3 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant7 Sept 2026Publicly observed
NIH SBIR/STTR award: Enhancing antigen sensitivity of BCMA CAR T cells for durable clinical responses inmultiple myeloma
USD 373,452.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jul 2026Publicly observed
NIH SBIR/STTR award: Development of a modular customizable screening platform for chimeric antigenreceptor optimization
USD 322,576.00 · National Center for Advancing Translational Sciences · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.